-
|
PR Newswire –
1:13 PM ET 05/23/2022
CINCINNATI, May 23, 2022 Meridian Bioscience (VIVO), Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.
|
-
|
Benzinga –
4:31 PM ET 05/19/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
PR Newswire –
3:33 PM ET 05/17/2022
CINCINNATI, May 17, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix.
|
-
|
Benzinga –
4:48 PM ET 05/09/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
3:10 PM ET 05/06/2022
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
|
-
|
Benzinga –
9:08 AM ET 05/06/2022
Meridian Bioscience reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Meridian Bioscience beat estimated earnings by 40.43%, reporting an EPS of $0.66 versus an estimate of $0.47. Revenue was up $25.97 million from the same period last year.
|
-
|
Reuters –
8:22 AM ET 05/06/2022
Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS. * SEES FY ADJUSTED EARNINGS PER SHARE $1.30 TO $1.40. * Q2 REVENUE ROSE 30 PERCENT TO $111.2 MILLION. * SEES CONSOLIDATED FY NET REVENUE $330.0 MILLION TO $345.0 MILLION.
|
-
|
PR Newswire –
8:00 AM ET 05/06/2022
CINCINNATI, May 6, 2022 Meridian Bioscience, Inc. (VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights: Jack Kenny, Chief Executive Officer, commented, "Meridian delivered another strong quarter.
|
-
|
Benzinga –
5:13 AM ET 05/06/2022
** Brookfield Renewable is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. ** Tile Shop Holdings is expected to report quarterly earnings at $0.09 per share on revenue of $95.03 million. ** Intercept Pharmaceuticals is projected to report quarterly loss at $0.90 per share on revenue of $90.49 million.
|
-
|
Benzinga –
4:39 PM ET 05/05/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
1:22 PM ET 05/05/2022
Meridian Bioscience is set to give its latest quarterly earnings report on Friday, 2022-05-06. Analysts estimate that Meridian Bioscience will report an earnings per share of $0.47. Meridian Bioscience bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
|
-
|
Benzinga –
4:36 PM ET 05/04/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Reuters –
9:18 AM ET 05/02/2022
Meridian Bioscience Inc (VIVO): * MERIDIAN ACQUIRES EUPROTEIN TO FURTHER EXPAND RECOMBINANT PROTEIN CAPABILITIES. * Meridian Bioscience Inc (VIVO) - HAS ACQUIRED, THROUGH SUBSIDIARY MERIDIAN LIFE SCIENCE, INC, SUBSTANTIALLY ALL OF ASSETS OF EUPROTEIN INC Source text for Eikon: Further company coverage:
|
-
|
PR Newswire –
8:47 AM ET 05/02/2022
CINCINNATI, Ohio, May 2, 2022 Meridian Bioscience (VIVO), Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022.
|
-
|
Benzinga –
4:33 PM ET 04/26/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
4:55 PM ET 04/22/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
4:31 PM ET 04/07/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
PR Newswire –
8:35 AM ET 04/07/2022
CINCINNATI, April 7, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022.
|
-
|
Benzinga –
10:14 AM ET 04/01/2022
According to Benzinga Pro, during Q1, Meridian Bioscience earned $15.34 million, a 130.43% increase from the preceding quarter. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.
|
-
|
PR Newswire –
2:37 PM ET 03/29/2022
CINCINNATI, March 29, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy enabling the earliest detection of cancer using non-invasive liquid biopsy.
|
Page:
|
Today's and Upcoming Events
-
VIVO to announce Q3 earnings (Unconfirmed)
Past Events (last 90 days)
-
VIVO announced Q2 earnings.
Data provided by Thomson Reuters © 2022
|